title: Reducing the duration of untreated first-episode psychosis -- effects on baseline social functioning and quality of life.
abstract: OBJECTIVE
  Long duration of untreated psychosis (DUP) is associated with poorer outcome. The TIPS study demonstrated that DUP can be reduced through early detection (ED). As quality of life (QoL) is associated with DUP it is expected that reduction of DUP leads to better QoL.
  
  
  METHODS
  Consecutive first-episode patients with a DSM-IV diagnosis of non-organic, non-affective psychosis were included, 281 patients gave informed consent and 263 completed a full evaluation of QoL.
  
  
  RESULTS
  There were no differences in subjective QoL between ED and No-ED groups attributable to reduction in DUP. There were significant bivariate differences in frequency of family and social contacts in favor of the ED group, but multivariate analyses indicated that these differences were based on differences in sample characteristics.
  
  
  CONCLUSIONS
  Deterioration in QoL may precede overt symptom formation. Focus on functional loss in ED educational campaigns may identify risk subjects earlier in the course of the disorder.
authors.affiliation: Department of Psychiatry, Yale University, New Haven, CT, USA. ingri.melle@medisin.uio.no
authors.forename: I
authors.initials: I
authors.lastname: Melle
authors.forename: U
authors.initials: U
authors.lastname: Haahr
authors.forename: S
authors.initials: S
authors.lastname: Friis
authors.forename: K
authors.initials: K
authors.lastname: Hustoft
authors.forename: J O
authors.initials: JO
authors.lastname: Johannessen
authors.forename: T K
authors.initials: TK
authors.lastname: Larsen
authors.forename: S
authors.initials: S
authors.lastname: Opjordsmoen
authors.forename: B R
authors.initials: BR
authors.lastname: Rund
authors.forename: E
authors.initials: E
authors.lastname: Simonsen
authors.forename: P
authors.initials: P
authors.lastname: Vaglum
authors.forename: T
authors.initials: T
authors.lastname: McGlashan
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011379:Prognosis; D011618:Psychotic Disorders / Q000175:diagnosis / Q000523:psychology* / Q000628:therapy*; D011788:Quality of Life; D012307:Risk Factors; D012919:Social Behavior
chemical_list: D014150:Antipsychotic Agents